u/PuzzleheadedDebt119

The author argues RMTG's newly detailed ISSCA AI Clinical Intelligence Platform is a real product, not vague AI talk, with a reasoning corpus of 1.6 million longitudinal health records and over 10,000 clinical studies. The commercial model adds four revenue channels (SaaS subscriptions via the existing physician network, patient longevity memberships, conference-based sales, and an ISSCA AI certification program) on top of existing training and product revenue, creating high-margin recurring revenue. The author cites Q2 revenue of $4.02M with $565K operating income and expects Q3 to be the tell, seeing close to $8M in revenue with potential upside if AI platform traction builds in the 30+ country, thousands-of-doctors network. Main risk implied is whether the SaaS and membership channels actually gain traction.